Skip to main content
Message Font: Serif | Sans-Serif
 
No. of Recommendations: 0
Aphria invested in Tetra Biopharma a number of years ago and has maintained its investment in the company. So you can imagine their surprise when Tetra Biopharma's CEO announced to their board of directors, on which Aphria holds a seat, that Tetra recently discovered that their very own latest acquisition, Panag Pharma, has a drug it's been testing for over ten years on coronavirus symptoms, ARDS and CRS, aptly named "ARDS-003", and among the dozen or so published research articles on the drug molecule are shown, I would say, astounding results when studies compared the standard of care drugs to it. The links to that research may be obtained for the Tetra IR department. ARDS, if you don't know, is the acronymn for one of the major causes of death in COVID-19, which is "Acute Respiratory Distress Syndrome". You heard that right; their wholly-owned subsidiary has been researching their highly promising ARDS drug for over one decade, and Tetra didn't even know it because they were already convinced it's pipeline they knew of was worth their price. Tetra already had ARDS-003 going as their PPP-003 drug because of its power to help with ophthalmologic conditions, including knocking out inflammation in multiple areas in the human eye. Once top management was informed by a Panag researcher, that Hey, we have this drug that stops cytokine release storms (CRS) and ARDS symptoms, the major killers of the COVID-19 virus, the company quickly huddled up and realized they had an unbelievable opportunity. I'll say so. Try for comparison's sake going shopping at Walmart and when you get home, the Cracker Jack box prize inside has a twenty carat diamond inside the wrapping.

Needless to say, coming out of the huddle, Tetra Biopharma made this ARDS (and CRS) drug their number one drug to focus on. They are fast-tracking it as injectable PPP-003 but naming it ARDS-003 for obvious reasons. They are still keeping the drugs they currently have in Phase II and III clinical trials moving forward, and PPP-003 for eyes will continue moving forward, but they are now calling ARDS-003 their lead drug. So with that, let's take a look at some salient points about this gift from God that fell into their lap:

The List To Know:
ARDS-003 has zero FDA-approved competition.
There are ZERO FDA-approved drug treatments for ARDS & CRS (major killers of COVID-19 patients).
They are fast-tracking it through FDA approved clinical trials.
It's first in human clinical trials!
FDA said the nonclinical program was appropriate to now initiate studies in COVID-19 patients.
FDA said NO other safety studies are required to initiate Phase 2 studies in SARS-COV-2 patients.
The prior studies over ten years results in decreased cost to do the FDA drug program.
No human metabolite toxicology safety studies are required to begin Phase 1 & 2 clinical trials.
The FDA also provided detailed feedback on the proposed Phase 1 and 2 clinical trial protocols.
FDA repeatedly stated they want clinical trials for COVID-19 to begin as soon as possible.
FDA stressed trials be designed to rapidly assess if ARDS-003 is effective in COVID-19 patients.
The U.S. and Canadian governments and the World Health Organization are to review the studies.
The Phase 1 ARDS clinical trial on healthy volunteers is expected to begin late September 2020.
This Phase 1 clinical trial will last two months and the analysis then reported to the FDA.
COVID-19 patients will be studied parallel to the Phase 1 clinical trial in this September.
ARDS-003 was designed to treat COVID-19 type viruses, like SARS, another coronavirus.
ARDS-003 therefore has not needed to be redesigned or repurposed for COVID-19 (a coronavirus).
ARDS-003 is to be studied in COVID-19 patients at risk of developing ARDS.
ARDS-003 is in the Coronavirus Treatment Acceleration Program (CTAP), an FDA expedited process.
It's injectable PPP-0003, which was created from cannabinoids or cannabis, as you will.
It's a synthetic derivative of a phytocannabinoid (a cannabis component).
It has been in about a dozen research studies.
It reduces or stops lung tissue inflammation (what is killing COVID-19 patients).
It significantly knocks down the effect of cytokine storms (which is killing COVID-19 patients).
It reduces the number of cytokines themselves.
Reduces or stops sepsis for the above reasons.
Reduces or stops kidney failure for the above reasons.

It's hoped by Tetra and FDA that the new drug type favorably impacts COVID-infection health care.
It's also holds promise for it to reduce the negative health outcomes of post-infection COVID-19.

Tetra is working to have drug approval in early 2021 on the fast track due to the COVID crisis. Keep your eyes on this company, and like Aphria, they are a publicly traded company, too. This could significantly impact Aphria going forward. The research team at Panag Pharma are close associates with Dr. Raphael Mechoulam, known as the Father of the Endocannabinoid System, who discovered it, THC and the Entourage Effect. So these are significant researchers in this cannabinoid pharmaceutical space.
Print the post  

Announcements

What was Your Dumbest Investment?
Share it with us -- and learn from others' stories of flubs.
When Life Gives You Lemons
We all have had hardships and made poor decisions. The important thing is how we respond and grow. Read the story of a Fool who started from nothing, and looks to gain everything.
Contact Us
Contact Customer Service and other Fool departments here.
Work for Fools?
Winner of the Washingtonian great places to work, and Glassdoor #1 Company to Work For 2015! Have access to all of TMF's online and email products for FREE, and be paid for your contributions to TMF! Click the link and start your Fool career.